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Scandinavian scale), type of stroke (ischemic vs hemorrhagic, by infor-
mation from computed tomography or magnetic resonance scanning),
alcohol consumption, smoking status and other cardiovascular risk fac-
tors (e.g., diabetes and atrialﬁbrillation). The authors found a borderline
increased risk of ischemic stroke in patients with migraine, selected by
triptan utilization; stratifying by gender and type of stroke, only theMigraine
Stroke
TriptansMigraine is a neuro-vascular disease characterized by recurrent at-
tacks of moderate to severe headache, lasting 4–72 h and associated
with nausea/vomiting and sensitivity to light and noise. Its remarkable
prevalence together with the high likelihood of overtreatment carries
signiﬁcant clinical and economic implications. Although plenty of
studies have investigated the possible association of migraine and
cardiovascular diseases, especially stroke, the nature of this complex, bi-
directional link is still obscure (Schurks et al., 2009).
From a clinical standpoint, it is important to differentiate migraine-
induced stroke (i.e., a rare and distinct occurrence of stroke following
typical attack of migraine with aura, also known as “migrainous infarc-
tion”), from migraine-related stroke. In fact, the latter occurs remotely
from a migraine attack and probably implies different mechanisms.
The contribution of drugs in the occurrence of migraine is a matter of
current debate; the documented vascular effect of migraine-speciﬁc
medications, namely triptans and ergot derivatives, has received in-
creasing attention because of their complex vasoconstricting properties
(Chan et al., 2011),whichmight increase the risk of serious cardiovascu-
lar events (Roberto et al., 2014, 2015).
In this scenario, the cohort study byAlbieri and colleagues addressed
the relationship between stroke and migraine in the Danish population
using triptans, and characterized the risk in terms of age, gender, stroke
severity and subtypes (Albieri et al., 2016). The study has the merit of
analyzing a 9-year period (2003−2011) through a record-linkage strat-
egy of the Danish Prescription and Stroke registries. Data quality is re-
markable, as important clinical covariates were considered in them.2016.02.039.
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risk for hemorrhagic stroke in women clearly emerged (RR = 1.41;
95% CI = 1.11–1.80). Notably, the estimated risk was closely associated
with age: highest among women aged 25–45 (RR: ~1.7), decreasing
rapidly thereafter with no association with triptan use after 55 years of
age. As regards severity, severe strokes (as measured by the Scandina-
vian Stroke Scale) were signiﬁcantly less prevalent among migraineurs
(RR = 0.77; 95% CI = 0.65–0.91).
Deﬁning the actual role of triptans in precipitating stroke is chal-
lenging for a number of methodological issues. In the study by
Albieri et al., triptans were used as a proxy of migraine (or, better,
of severe migraine): thus, no information on the difference between
people exposed to triptans and other migraineurs is available. In ad-
dition, patients with migraine have multiple treatment options (an-
algesics for advanced symptoms, prophylactic therapy for more
severe cases, ergot derivatives as an alternative to triptans), but
the variety of pattern of use (both in frequency and combinations)
and the multiple indications of most options do not allow to stratify
migraineurs for therapy nor to attribute stroke occurrence to a spe-
ciﬁc therapy rather than a combination of them or only to the mi-
graine status. Another general limitation of observational studies
aiming to evaluate antimigraine therapies, especially symptomatic
treatment, is represented by the time distance between prescription
and actual use: since migraineurs are very careful to have medica-
tion available when needed to control attacks quickly, temporal cor-
relations between triptan intake and stroke occurrence cannot be
easily studied.
The data by Albieri and coworkers are in line with recent literature,
including variousmeta-analyses, documenting both increased risk of is-
chemic and hemorrhagic stroke in women (Spector et al., 2010; Sacco
et al., 2013). Surprisingly, they noticed a lower prevalence of cardiovas-
cular risk factors among patients with stroke that were also triptan
users; the risk was unrelated to the number of dispensed prescriptions
(lack of a dose-response effect). Taken together, these ﬁndings
strengthen the notion that, on one hand, the underlying disease per se
contributes largely to the observed risk and suggest a migraine-
speciﬁc etiology of stroke (which might be different from that ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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that in Denmark triptans are likely to be prescribed taking into account
known cardiovascular contraindications. This study underlines, once
more, the importance of a careful risk/beneﬁt assessment before pre-
scribing triptans for migraine. In particular, both ischemic and hemor-
rhagic risks should be considered depending on individual patient
characteristics: middle-agedwomenwithout cardiovascular risk factors
are at increased risk of hemorrhagic stroke and should be screened for
additional bleeding risk factors thatmay increase the risk of hemorrhag-
ic stroke such as concomitant hypercoagulability states. In men, atten-
tion should be paid to undetected subclinical cardiovascular diseases
that may precipitate ischemic stroke, such as patent foramen ovale
(PFO).
From a research standpoint, important unanswered questions
regard (a) the explanation for increased risk of hemorrhagic stroke
in migraine and (b) whether a role of triptans per se exists. The for-
mer (i.e., underlying mechanisms subtending the hemorrhagic
risk) is still hypothetical: activated platelet aggregation and sero-
tonin release caused by subclinical artery dissection, hypercoagu-
lability as a consequence of endothelial dysfunction or arterial
microemboli due to PFO have been hypothesized (Mawet et al., 2015).
In this context, the potential role of additional concomitant drugs inter-
fering with platelet or endothelial functions (e.g., antithrombotics and
nonsteroidal antiinﬂammatory drugs, statins) deserves further investi-
gation. The latter (i.e., the pharmacological basis of vasoconstriction
induced by triptans and ergot derivatives and real deﬁnition of the
drug-related component in stroke occurrence) has been largely investi-
gated, but still incompletely appreciated; in fact the ergots were origi-
nally developed as sympatholytics, but it was later suggested that
their antimigraine effect was probably mediated by vasoconstriction
of cranial blood vessels, through a variety of receptors including seroto-
nin, dopamine and noradrenaline receptors (Chan et al., 2011).
In conclusion, basic scientists have a topic for future studies address-
ing the mechanistic basis of migraine-speciﬁc etiology: clarifying thepathophysiological mechanisms underlying migraine may help both
clinical practice and the identiﬁcation of additional pharmacological
targets, which may vary depending on the type of migraine (i.e., with
or without aura). As a matter of fact, mouse models and genetics
(genome-wide association studies) are becoming an attractive source
of clinical information to identify novel indicators of susceptibility
(e.g., polymorphism inmethylene tetrahydrofolate reductase) and selec-
tive therapeutic agents (e.g., monoclonal antibodies targeting calcitonin
gene-related peptide), which may potentially target not only migraine
but also underlying comorbidities such as epilepsy and depression
(Ferrari et al., 2015). In the era of precision medicine, the identiﬁcation
and validation of biomarkers will represent the next research challenge.References
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